New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
WTVM,
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
Wave 3 News,
In vitro studies suggest TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local…
New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
Hawaii News Now,
In vitro studies suggest TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local…
New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
Yahoo! Finance USA,
In vitro studies suggest TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local…
New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
Morning Star,
New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a…
New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
WWSB,
In vitro studies suggest TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local…
New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
Yahoo!,
In vitro studies suggest TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local…
New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
Biospace,
In vitro studies suggest TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local…
Synovitis and psoriatic arthritis: Similarities and differences
Medical News Today,
Synovitis is a condition wherein the synovial stratum inside the joint has inflammation.
Johnson
MarketScreener,
SPRING HOUSE, PENNSYLVANIA, March 25, 2022 - The Janssen Pharmaceutical Companies of Johnson
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
ProfitQuotes.com,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
Tech Register,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
Benzinga,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
Yahoo! Finance USA,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
KCBD,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
Wave 3 News,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
Fox 19,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
WFMZ-TV 69,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
NBC12,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
KPLC 7 News,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
WWSB,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
WTVM,
SPRING HOUSE, Pa., March 25, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
WALB,
SPRING HOUSE, Pa., March 25, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
Hawaii News Now,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
PR Newswire,
Post hoc analysis shows TREMFYA responders reported clinically significant improvements across measures of social and sexual…
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm
Morning Star,
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA® (guselkumab…
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Spoke,
The NMA indirectly compared all published Phase 3 data for approved treatments for adults with active PsA TREMFYA ranked…
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
VB Profiles,
The NMA indirectly compared all published Phase 3 data for approved treatments for adults with active PsA TREMFYA ranked…
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Ticker Tech,
The NMA indirectly compared all published Phase 3 data for approved treatments for adults with active PsATREMFYA ranked highest…
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
ProfitQuotes.com,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Tech Register,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
WWSB,
The NMA indirectly compared all published Phase 3 data for approved treatments for adults with active PsA SPRING HOUSE, Pa., Jan.
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
KCBD,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (...
Finanzen.ch,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Hawaii News Now,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
KPLC 7 News,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Fox 19,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Wave 3 News,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Morning Star,
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance…
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
PR Newswire,
The NMA indirectly compared all published Phase 3 data for approved treatments for adults with active PsA TREMFYA ranked…
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Yahoo! Finance USA,
The NMA indirectly compared all published Phase 3 data for approved treatments for adults with active PsA TREMFYA ranked…
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
WFMZ-TV 69,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
NBC12,
The NMA indirectly compared all published Phase 3 data for approved treatments for adults with active PsA SPRING HOUSE, Pa., Jan.
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Benzinga,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
WALB,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Yahoo!,
The NMA indirectly compared all published Phase 3 data for approved treatments for adults with active PsA TREMFYA ranked…
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Biospace,
SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Psoriatic Arthritis Detection: Screening Tools for Dermatologists
Medscape,
This transcript has been edited for clarity. Joseph F. Merola, MD, MMSc: Hi. I'm Dr Joseph Merola.
Johnson
MarketScreener,
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 - The Janssen Pharmaceutical Companies of Johnson
New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Impro...
Finanzen.ch,
SPRING HOUSE, Pa., April 23, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
ProfitQuotes.com,
Skin clearance rates were maintained at five years with 55.5 percent of patients achieving an Investigator's Global Assessment…
New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
Finanzen.ch,
SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
Morning Star,
New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in…
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
ProfitQuotes.com,
Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients…
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
VB Profiles,
Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients…
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
Spoke,
Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients…
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
Finanzen.ch,
SPRING HOUSE, Pa., Nov. 6, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
Finanzen,
SPRING HOUSE, Pa., Nov. 6, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
Bradford Era,
SPRING HOUSE, Pa., Nov. 6, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
TREMFYA® (guselkumab) Reduced Fatigue Over 52 Weeks In Adult Patients With Psoriatic Arthritis In Two Phase 3 Clinical Trials
The Street,
Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients…
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
The Courier Express,
SPRING HOUSE, Pa., Nov. 6, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
WFMZ-TV 69,
SPRING HOUSE, Pa., Nov. 6, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
Yahoo! Finance USA,
Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients…
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
KPVI,
SPRING HOUSE, Pa., Nov. 6, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
Morning Star,
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials…
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
PR Newswire,
Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients…
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
Benzinga,
SPRING HOUSE, Pa., Nov. 6, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
Biospace,
SPRING HOUSE, Pa., Nov. 6, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Inc.